Linda Skibsted Kornerup,Frederik Kraglund,Hendrik Vilstrup et al.
Linda Skibsted Kornerup et al.
Background: Thyroid hormone levels are associated with HCC in animal studies. We examined HCC risk and prognosis in patients with thyroid disease. Methods...
CD8 TRM-like T cells expressing perforin and IFN-γ define a pediatric activated T-cell acute liver failure endotype [0.03%]
表达穿孔素和干扰素-γ的类似CD8组织驻留记忆T细胞定义了儿科急性肝衰竭的一种活化的T细胞亚型
Tamir Diamond,Catherine A Chapin,Caroline J Diorio et al.
Tamir Diamond et al.
Background: Activated T-cell pediatric acute liver failure (TC-PALF) is the most common cause of non-acetaminophen PALF, with poor transplant-free survival. Livers in TC-PALF are infiltrated by effector cytotoxic T lympho...
Pain, uncertainty, and lack of clinical support drive emergency department utilization in cirrhosis: A qualitative study [0.03%]
肝硬化患者因疼痛、不确定性以及缺乏临床支持而使用急诊科：一项定性研究
Swetha Parvataneni,Nicholas E Harrison,Bridget Hawryluk et al.
Swetha Parvataneni et al.
Background: Individuals with cirrhosis frequently require Emergency Department (ED) care, with some experiencing repeated ED use, yet little is known about the patient and caregiver perspectives driving decisions to visit...
Thomas Hunold,Neehar D Parikh
Thomas Hunold
Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality worldwide, with most cases arising in patients with cirrhosis or chronic hepatitis B. Current guidelines recommend semi-annual ultrasound with or without alpha-fe...
Second-line tacrolimus and mycophenolate mofetil in difficult-to-treat autoimmune hepatitis [0.03%]
二线他克莫司和霉酚酸酯莫非酯治疗难治性自身免疫性肝炎
Alena Laschtowitz,Clara Vom Endt,Martin Kluge et al.
Alena Laschtowitz et al.
Introduction: Azathioprine with corticosteroids is the first-line treatment for patients with autoimmune hepatitis (AIH). However, around 20% of patients require treatment alternatives, and second-line therapy for AIH is ...
The diagnosis and management of portal hypertension in cirrhosis: The Gastroenterological Society of Australia consensus [0.03%]
澳大利亚胃肠病学会肝硬化门脉高压诊治共识陈述
Avik Majumdar,Jacinta Holmes,Stuart K Roberts et al.
Avik Majumdar et al.
Background: In Australia, chronic liver disease is now the third leading cause of premature death in people aged 50-59 years, and the fourth leading cause in all other 5-year age groups from 35 to 70 years in Australia. A...
Practice Guideline
Hepatology communications. 2026 Mar 31;10(4):e0934. DOI:10.1097/HC9.0000000000000934 2026
The management of hepatorenal syndrome-acute kidney injury (HRS-AKI): A national survey of hepatology provider practices [0.03%]
肝病医生关于肝肾综合征-急性肾损伤(HRS-AKI)管理实践的全国调查分析
Giuseppe Cullaro,Gene Y Im,Shaun Chandna et al.
Giuseppe Cullaro et al.
Background: Hepatorenal syndrome-acute kidney injury (HRS-AKI) is associated with high mortality in cirrhosis. Recent FDA approval of terlipressin and updated clinical guidance have expanded management options, but real-w...
Spatial and functional polarization of cancer-associated fibroblasts with CXCR4-mediated immune modulation in hepatocellular carcinoma [0.03%]
肝细胞癌中CXCR4介导的免疫调节的癌相关成纤维细胞的空间和功能极化
Daichi Nakamura,Takahiro Nishio,Yo Oguma et al.
Daichi Nakamura et al.
Background: Cancer-associated fibroblasts (CAFs) represent a predominant cell population in the tumor microenvironment (TME) of hepatocellular carcinoma (HCC). How the spatial distribution of CAF subtypes relates to immun...
Construction of TLS-related gene signature for predicting prognosis and immunotherapy response in hepatocellular carcinoma [0.03%]
肝癌中用于预测预后和免疫治疗反应的TLS相关基因特征的构建
Jian-Rong Li,Li-Xin Pan,Jia-Yong Su et al.
Jian-Rong Li et al.
Background: Tertiary lymphoid structures (TLSs) are critical components of the tumor microenvironment in HCC. However, the role of TLS-related molecules in predicting HCC outcomes and guiding immunotherapy remains unexplo...
Liver test pattern and histologic bile duct injury do not predict response to treatment of immunotherapy hepatotoxicity [0.03%]
肝功能检查模式和组织学胆管损伤不能预测免疫治疗肝毒性的反应
Benjamin Rabin,Michael Li,Jordan S Sack et al.
Benjamin Rabin et al.
Background and aims: Immune checkpoint inhibitor (ICI) cholangitis is an uncommon immune-related adverse event affecting the biliary ducts that is considered distinct from ICI hepatitis. This study examines whether the li...
Multicenter Study
Hepatology communications. 2026 Mar 26;10(4):e0922. DOI:10.1097/HC9.0000000000000922 2026